NEW YORK (GenomeWeb) – Liquid biopsy is continuing to attract new entrants as existing attention in the field has turned away from tumor profiling in advanced cancers to applications like therapy monitoring, residual disease detection, and early cancer screening.
One new name, Lexent Bio, is planning to advance a technology for measuring and monitoring drug response in later-stage cancer patients, which it believes it can also translate to detection of minimal residual disease in patients who have had a tumor surgically removed.